Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15424987 | 0.76 | KDM1A (1.00) | KDM1AMAOBDRD2HTR2ASLC6A4 | |
| SCHEMBL15411742 | 0.76 | KDM1A (1.00) | KDM1AMAOBDRD2HTR2ASLC6A4 | |
| SCHEMBL21101609 | 0.76 | KDM1A (1.00) | KDM1AMAOBDRD2HTR2ASLC6A4 | |
| SCHEMBL15411743 | 0.76 | KDM1A (1.00) | KDM1AMAOBDRD2HTR2ASLC6A4 | |
| SCHEMBL19513651 | 0.76 | KDM1A (1.00) | KDM1AMAOBDRD2HTR2ASLC6A4 | |
| SCHEMBL20633815 | 0.74 | KDM1A (0.64) | KDM1AMAOBACHEDRD2HTR2A | |
| SCHEMBL2004615 | 0.74 | CCR3 (1.00) | CCR3ACHEALDH1A1MEN1KMT2A | |
| SCHEMBL4433102 | 0.74 | CCR3 (0.73) | CCR3ACHEALDH1A1CXCR4DRD2 | |
| SCHEMBL15140944 | 0.74 | CCR3 (0.73) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL1002852 | 0.74 | MEN1 (0.81) | CCR3ACHECCR5DRD2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688568-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-29 | — | — | EP | claimed |
| WO-2012135113-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-04 | — | — | WO | claimed |
| US-20210100800-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | INSTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-08 | — | — | US | disclosed |
| EP-2688568-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012135113-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210100800-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | CDK6, KDM1B, KDM6B | KDM1A 7/4885MAOB 1514/4885CCR3 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.